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Increased Risk for Aplastic Anemia and Myelodysplastic
Syndrome in Individuals Lacking Glutathione
S-Transferase Genes
Joanne F. Sutton, MD,1,2,3 Michael Stacey, PhD,4 William G. Kearns, PhD,1 Thomas S. Rieg, PhD,3
Neal S. Young, MD,1 and Johnson M. Liu, MD1*
BACKGROUND
Acquired aplastic anemia (AA) and myelodysplastic
syndrome (MDS) are distinct but related bone marrow
failure syndromes, diagnosed by marrow morphology.
Approximately 20% of MDS cases present with a hypo-
cellular marrow and, in turn, AA may evolve to MDS or
develop cytogenetic abnormalities [1]. For each disorder,
the etiology is unknown, however, there may be gene-
environment interactions that predispose to disease [1,2].
For example, an increased incidence of AA has been
observed in Asia [3]. Glutathione S-transferase (GST) is a
key biometabolic enzyme for a number of chemical toxins,
including the organophosphates, alkylating agents, epox-
ides, and polycyclic aromatic hydrocarbons [4]. Low GST
activity may genetically predispose some individuals to
marrow failure, perhaps as a result of increased suscept-
ibility to endogenous or environmental toxins.
Glutathione S-transferase M1 (GSTM1) and T1
(GSTT1) genes are polymorphic in humans. It has been
well established that the frequencies of GSTT1 null and
GSTM1 null genotypes in healthy human subjects vary
greatly among different ethnic populations and can reach
frequencies as high as 0.58 (GSTT1 null) and 0.67 (GSTM1
null) in Asians [5–10]. Racial or ethnic variation in bone
marrow failure risk may reflect innate biological suscept-
ibility as well as differences in environmental exposures or
socioeconomic and demographic factors [1,11].
Recently, increased frequencies of GSTM1 and GSTT1
gene deletions were reported in 57 Korean patients with
AA [12]. Similarly, a higher risk for MDS was noted in
individuals with GSTT1 gene deletions, although subse-
quent studies of patients with different ethnicities yielded
conflicting results [13–19]. Here, we have determined the
frequency of homozygous GSTM1 and GSTT1 gene
deletions in an ethnically heterogeneous cohort of AA
and MDS patients referred to the National Institutes of
Health. We also expanded our study to determine if there
Background. Aplastic anemia (AA) and
myelodysplastic syndrome (MDS) are marrow
failure states that may be associated with chro-
mosomal instability. An absence of the glu-
tathione S-transferase (GST) enzyme may
genetically predispose individuals to AA or
MDS. Procedure and Results. To test this
hypothesis, we determined the GSTM1 and
GSTT1 genotypes in a total of 196 patients using
multiplex PCR. The GSTT1 null genotype was
found to be overrepresented in Caucasian,
Asian, and Hispanic patients with either AA or
MDS. We confirmed a difference in the expec-
ted frequency of the GSTM1 null genotype in
CaucasianMDSpatients.ThedoublenullGSTM1/
GSTT1 genotype was also overrepresented in
Caucasian AA and MDS patients. In our popula-
tion, 26%ofAApatients and40%ofMDSpatients
had a chromosomal abnormality identified by
karyotypeorFISHanalysesforchromosomes7and
8. Patients with AA and theGSTT1 null genotype
had an increased frequency of chromosomal
abnormalities (P¼ 0.003). Conclusion. There
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was a difference in the frequency of chromosomal abnor-
malities in patients with GSTM1 or GSTT1 null genotypes
compared to those with GSTM1 or GSTT1 present.
STUDY DESIGN AND METHODS
The study population included 196 patients, 108
diagnosed with either moderate or severe AA and 88 with
MDS, referred to the National Heart Lung and Blood
Institute, Hematology Branch between 1997 and 2000
(age range, 3–85 years; median age, 41 years; 112 males
and 84 females). Standard diagnostic criteria were
utilized, and no patients with congenital bone marrow
failure (Fanconi anemia) were included. Race was self-
reported by each patient (142 Caucasian, 28 Hispanic,
16 Black, and 10 Asian). To assure patient anonymity, no
other patient identifiers were used. Cytogenetic data by
conventional karyotype of the bone marrow were available
for 185 (94%), and a bone marrow pellet was available for
113 (57%). Control values were based on selecting the
median value of previously published gene frequencies of
healthy human subjects sorted by race [5–10].
DNA was isolated from bone marrow samples using
Qiagen tissue prep kit according to the manufacturer’s
guidelines (Qiagen, Valencia, CA). Analysis for the
GSTM1 and GSTT1 genes was performed by multiplex
PCR, as previously described [5]. In brief, 30 ng of isolated
DNA was analyzed in a single assay for GSTM1, GSTT1,
andCYP1A1. All primers were custom synthesized at Life






GCATTTGGAAGTGCTC-30). A 50 ml reaction mixture
containing 30 pmol of each primer, 200 mmol dNTPs, 5 ml
of 10 PCR buffer, 2 U Taq DNA polymerase (Qiagen
PCR Core Kit) was amplified in a PTC-200 Peltier
Thermal Cycler. PCR conditions were as follows: initial
melting 948C 5 min, followed by 35 cycles of melting
948C 2 min, annealing 598C 1 min, extension 728C
1 min, and a final extension at 728C 10 min. The PCR
products were analyzed on an ethidium bromide stained
2% agarose gel. The presence or absence of GSTT1 and
GSTM1 genes was determined by examination for
characteristic bands at 480 bp (GSTT1) and 215 bp
(GSTM1). A band at 312 bp corresponding to the internal
control (CYP1A1) was used to confirm successful PCR
amplification.
Fluorescent in situ hybridization (FISH) was performed
on 113 patients with available bone marrow pellets and
14 normal bone marrow controls, using alpha satellite
DNA probes for chromosomes 7 and 8 (VYSIS, Inc.,
Downer’s Grove, IL). A probe mixture was applied to the
target area and codenatured at 758C for 3 min followed by
hybridization at 428C. Approximately 300 interphase
nuclei per slide were scored for monosomy 7 and trisomy 8
as per criteria established by Vysis. Aneuploidy was
established for monosomy 7 as >2.91% and for trisomy 8
as >2.8% of cells, based on results obtained in the normal
samples.
Descriptive analyses included gene frequencies and
contingency tables. Associations between variables were
tested with chi-square and Fisher exact test where
appropriate. Standard odds ratio and power were com-
puted. Significance was obtained for P< 0.05.
RESULTS AND DISCUSSION
Frequency of GSTM1 and GSTT1 Null Genotypes in
Bone Marrow Failure Patients Stratified by Race
Control values were selected (see ref. [8], expected
frequencies, Table I) for each genotype based on the
median value of previously published gene frequencies of
healthy human subjects sorted by race. A recent study
reported metabolic gene polymorphism frequencies for
over 15,000 control subjects. Significant differences were
observed between races, as expected, but much less
heterogeneity was observed between White populations
from different countries and no differences were seen by
age, sex, or type of controls (hospital patients vs. popu-
lation controls).
The GSTT1 null genotype was overrepresented in
Caucasian, Hispanic, and Asian patients with either AA or
MDS (Table I). In contrast, the GSTM1 null genotype was
significantly overrepresented only in Caucasian MDS
patients. No significant association was found for the null
genotypes in Black patients. The double null genotype was
significantly overrepresented only in Caucasians with
either AA or MDS.
Data on the GSTM1 and GSTT1 null genotypes in
marrow failure patients had previously been reported in
relatively homogeneous populations, many of which did
not include Black or Hispanic patients. For example, an
increased frequency of the GSTT1 null genotype was
reported in White American and Japanese MDS patients
[13,19]. Subsequent studies were unable to confirm this
result in British, French, and Japanese populations [14–
17]. Overrepresentation of the GSTM1 null genotype was
also reported in Greek MDS patients [18]. Acquired AA
has not been as extensively examined for GST gene
deletions. A study of 57 Korean AA patients reported a
significant increase in frequency of the GSTM1 or GSTT1
null genotypes [12], however, a Brazilian study of 37 AA
patients found no difference [20]. Ethnic variation in
frequency of GST polymorphisms and different environ-
mental exposures may account for the lack of concor-
dance in the literature. Our referral population was
ethnically and geographically diverse, and we have
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confirmed a difference in expected frequency of the
GSTT1 null genotype and AA or MDS in White and
Hispanic patients. However, unlike the Korean study, we
found no significant difference in frequency of theGSTM1
null genotype and AA.
A striking difference in frequency of the double null
GSTM1/GSTT1 genotype in Caucasian AA and MDS
patients was also observed. The double null genotype is an
important variable to investigate because nullizygosity for
GSTM1 and GSTT1 has been linked independently to
various cancers [4], and deletion of both genes may have
different significance from that of either gene alone.
High Frequency of Chromosomal Abnormalities Seen
in AA Patients With GSTT1 Null Genotype
Of the 187 patients with cytogenetics available, 26 of
102 (26%) patients with AA and 34 of 85 (40%) patients
with MDS had a chromosomal abnormality identified by
either conventional karyotype or FISH (Table II). Of those
patients with bone marrow pellets available, FISH
analyses identified monosomy 7 or trisomy 8 in 26 (44%)
AA patients, of whom 18 had no chromosomal abnorm-
alities identified by conventional karyotype. FISH ana-
lyses identified 27 (50%) MDS patients with either
monosomy 7 or trisomy 8, of whom 8 had a normal con-
ventional karyotype. The karyotype of each patient was
not known at the time that FISH was performed, in order to
prevent bias in scoring.
FISH analysis is known to be more sensitive than
conventional cytogenetics. In this setting, FISH was limit-
ed to determining aneuploidy of chromosomes 7 and 8,
which are two frequent chromosomal abnormalities
identified in MDS and AA [1,2]. Among the MDS pa-
tients, there was no significant correlation between the
GSTM1 null and GSTT1 null genotypes and chromosomal
abnormalities. However, a significant difference in
frequency of the GSTT1 null genotype was observed in
AA patients with chromosomal abnormalities, consistent
with findings from a Korean study [12]. The etiology of
chromosomal aberrations in MDS cannot be correlated to
a deletion of either theGSTT1 orGSTM1 gene. However, it
is possible that the GSTT1 null genotype decreases
an individual’s ability to biometabolize toxins, which
may lead to an increased risk for chromosomal aberrations
in AA.
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